Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context) between May 2013 and May 2016. Data collection took place between October 2016 and February 2017. Results: All 60 participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/ discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due to side effects occurred later for imatinib-or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with ≥MR 4.5 at interruption/discontinuation and ≥11-month follow-up who had not restarted treatment maintained the response. Conclusion: Although TKIs are used for long-term CML treatment, physicians sometimes recommend interruptions/discontinuations. In this study, interruptions/discontinuations were mainly caused by side effects or intolerance, rather than TFR attempts.
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid

Introduction
Adenosine triphosphate-competitive tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1, the driving oncoprotein of chronic myeloid leukemia (CML), revolutionized patient outcomes. After the introduction of imatinib in the early 2000s, the more potent second-generation drugs, dasatinib, nilotinib, and bosutinib, followed by the third-generation compound, ponatinib, enriched the therapeutic arsenal [1] .
Treatment discontinuation in CML is relatively frequent and although there has been an increased focus on treatment-free remission (TFR) as a new goal of therapy in CML, the interruption or discontinuation of therapy can occur for a myriad of other reasons in the real-life setting, e.g., to avoid worrying side effects including those predisposing to other chronic disease, eliminate lowgrade chronic toxicity that substantially impacts a patient's quality of life, and be freed up from the daily constraints of medication intake. Other reasons could be a pregnancy or the wish to conceive, no longer needing to be careful about drug-drug/food-drug interactions, and the financial burden of targeted therapy [2] [3] [4] [5] .
It also needs to be noted that this broad variety of reasons to interrupt TKI treatment in CML are either recommended by the treating physician (e.g., in the case of a TFR attempt, severe side effects, toxicity, pregnancy, and the wish to conceive) or not (i.e., non-adherence, which can be related to side effects and other reasons). Optimal adherence to CML therapy is of key importance to maximize treatment effectiveness. Two clinical studies (ADAGIO and Hammersmith) have proven a clear correlation between adherence and achieving optimal treatment response, and they revealed that non-adherence is indeed common in CML patients [6, 7] . In fact, it was demonstrated that non-adherence is associated with disease progression and a 3-foldhigher risk of poor treatment outcomes [7] .
Although most CML patients need life-long TKI treatment, the promising results of imatinib interruption in a small number of cases [8] [9] [10] prompted the launching of discontinuation trials. Subsequently, in the multi-centre Stopping Imatinib (STIM) study [11] [12] [13] , the CML8 (TWISTER) study from the Australasian Leukaemia and Lymphoma Group [14, 15] , and the multi-centre observational According to Stop Imatinib (A-STIM) study [16] , at least one-third of patients achieved TFR after interrupting treatment with imatinib. TFR clinical trials have also been conducted with second-generation TKIs, including ENESTfreedom [17] , ENESTop [18] , STOP 2G-TKI [19] , DADI [20] , and DASFREE [21] . Since mid-2017, TFR is included in the label of nilotinib, based on the ENESTfreedom and ENESTop trials [17, 18] . The use of second-generation TKIs does not seem to improve the results when compared to imatinib but does appear to impact on the median time from treatment start to the attempt to stop [22] . All the studies published so far clearly demonstrate that discontinuation is feasible and safe if performed in patients with a long-lasting deep molecular response (DMR), with no reports of disease progression or clonal evolution [22] . The last version of the 2013 European LeukemiaNet recommendations suggested continuing TKI therapy indefinitely and that discontinuation would be appropriate only in a controlled clinical trial [23] . Hughes and Ross [24] reported for the first time in 2016 how to move TFR into the clinical practice. A position on TKI discontinuation was also taken by the NCCN in the new 2017 version of the CML guidelines [25] .
In Belgium, national guidelines currently recommend staging of CML according to European LeukemiaNet [5, 25] or World Health Organisation [26] criteria, and initiating first-line treatment with imatinib, nilotinib, or dasatinib in chronic-phase (CP) patients, with careful monitoring of any adverse events (AEs) and potential drug interactions. Nilotinib, dasatinib, bosutinib, and ponatinib are considered for patients resistant or intolerant to their first-line TKI and also for advanced-phase patients. According to national guidelines, interruption or discontinuation of TKI treatment is recommended when severe skin rash or grade 3 hepatic toxicity occurs, or for female CP patients that have achieved a major molecular response (MMR) for ≥2 years and are planning to conceive. TFR attempts are only recommended in clinical trial settings for patients in a deep sustained response [27] .
Treatment discontinuation in CML is relatively frequent and, although there has been an increased focus on treatment free remission (TFR) as new goal of therapy in CML, therapy interruption or discontinuation can be for a myriad of other reasons in the real-life setting. In the existing literature, only a limited amount of data is currently available on this matter. We therefore conducted this trial to characterise TKI interruptions or discontinuations in Belgian CML patients and examine the reasons for TKI interruption or discontinuation in real-life situations with related national guidelines.
Methods
Study Design and Participants
The study on the interruption or discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia, SPAR- Eligible participants were CML patients who had ≥1 TKI interruptions/discontinuations (i.e., either interrupting temporarily or with the intention to discontinue indefinitely) of ≥4 continuous weeks (regardless of the reason) outside the context of a clinical trial between 31 May 2013 and 31 May 2016. Patients with an interruption of < 4 weeks were excluded to avoid evaluating those whose treatment was interrupted only briefly because of transient toxicity. We only included patients with a TKI interruption/discontinuation of ≥4 continuous weeks. As such, the study detected only the persistent phase of adherence according to the taxonomy of Vrijens et al. [28] (i.e., when a prescribed therapy is discontinued early), but not the non-implementation phase of adherence which may be more common in CML (i.e., the prescribed therapy is still taken but not in a fully compliant manner).
Study Objectives
The objectives of this observational study were to assess the predefined characteristics of patients and other parameters of TKI treatment interruption/discontinutation. A post hoc sub-group analysis was carried out, in patients followed for at least 11 months, of treatment interruptions/discontinuations that occurred between May 2013 and May 2015.
The predefined characteristics of patients and other outcomes of TKI treatment interruption/discontinuation were collected and analysed. The information collected as per protocol was inserted into an electronic case report form; no personally identifiable data was included.
Captured data consisted of the characteristics of patients, treatment interruption, and, if applicable, reinitiation of treatment. Patient characteristics included age, gender, Sokal risk score, CML phase, and disease duration. Characteristics of the treatment interruption included the duration and reason of the TKI interruption; the duration, type and line of TKI therapy that was interrupted; the time between TKI interruption and the first BCR-ABL1 RT-qPCR molecular test; and the depth of (molecular) response of the patient and its duration prior to TKI interruption.
Five levels of TKI response were used in this study: a complete haematological response (CHR), a complete cytogenetic response (CCyR), and 3 levels of MR, namely, MMR (also referred to as MR3; a 3-log reduction from the standardised baseline or ≤0.1% BCR-ABL1 on the International Scale as assessed by quantitative reverse-transcriptase PCR), MR4 (a 4-log reduction from the standardised baseline or ≤0.01% BCR-ABL1), and MR4.5 (a 4.5-log reduction from the standardised baseline or ≤0.0032% BCR-ABL1) or deeper [20] .
Outcomes
If the patient had reinitiated therapy, the outcomes of the treatment interruption/discontinuation that were captured included the date of reinitation and the depth of the response as well as the reasons for reinitation and the type of TKI used.
Statistical Methods
All analyses were performed with macro-enriched Microsoft Excel 2016 MSO (16.0.8201.2102) 32-bit version. They were performed on the overall population (for most outcomes), the subset of patients who interrupted/discontinued treatment due to pregnancy or the wish to conceive, and the subset of patients followed for at least 11 months.
All analyses were descriptive, and no statistical hypotheses were formulated. Missing data was excluded from the database when calculating percentages of patients or interruptions.
Some patients had multiple TKI treatment interruptions/discontinuations, so the number of interruptions/discontinuations was higher than the number of participants. Most analyses used variables related to interruptions/discontinuations (69 cases), so the number of interruptions/discontinuations was considered for calculating the statistical parameters instead of the number of participants (n = 60).
A contract research organization, XPE Pharma & Science, performed the statistical analysis under the supervision of the sponsor, Novartis.
Results
Study Population
Sixty CML patients participated in the study; 51 had 1 and 9 had 2 TKI interruptions/discontinuations, respectively ( Table 1 ). The total number of cap- 
Treatment Interruptions/Discontinuations
The median time between CML diagnosis and TKI treatment interruption/discontinuation was 363 weeks; patients were treated with TKIs (i.e., the specific TKI treatment that was interrupted/discontinued) for a median time of 169 weeks before the interruption/discontinuation.
Most TKI interruptions/discontinuations occurred while on imatinib or dasatinib, i.e., 49% (34/69) in patients taking imatinib and 29% (20/69) in patients taking dasatinib (the latter occurred mostly when taken as second-line treatment) ( Table 2 ).
The duration of the MR prior to TKI treatment interruption/discontinuation in the overall population ranged between 0 and 615 weeks; the median duration was 37 weeks. The respective durations of the MR prior to TKI interruption/discontinuation are described according to sub-characteristics in online supplementary (6/69 [9%] ). Of the interruptions/discontinuations due to side effects or intolerance, no significant influence of gender and age was observed (online suppl. Table 2 ).
For 17% (12/69) and 25% (17/69) of the interruptions/ discontinuations, patients had a low and intermediate Sokal risk score, respectively. For 1 interruption/discontinuation, the patient had a high Sokal risk score, and for 23% (16/69) no score was not available. The median duration of the treatment interruption/discontinuation was 112 days (Table 3) .
Twenty-eight of the 69 (41%) TKI interruptions/discontinuations were in patients on first-line TKI treatment, and a comparable number (25/69; 36%) in patients on second-line therapy (online suppl. Table 2 ).
Interruptions/discontinuations of imatinib treatment were the longest (median duration 186 days) when compared to other TKIs. The median duration of treatment interruption/discontinuation was longest in patients wishing to conceive (253 days) and shortest if they took place at the request of the patient (59 days). Interruptions/discontinuations due to side effects or intolerance lasted for a median 98 days, although this varied greatly, from 29 to 904 days.
Interruptions/discontinuations lasted a median of 24 weeks in study participants with an MMR (approx. 21 and 17 weeks in participants with MR4 and MR4.5 or deeper, respectively), while in those with CHR and CCyR, they lasted a median of 13 and 10 weeks, respectively ( Table  3 ). The median follow-up time between interruption/discontinuation and first molecular test did not vary much with different reasons for interruption/discontinuation (56 days for those due to side effects or intolerance, 49 days for TFR attempts, 47 days in patients wishing to conceive, and 48 days upon patient request). Those with less than MMR at treatment interruption/discontinuation had a shorter median time between interruption/discontinuation and first molecular test (Table 4) .
Of the 34 patients (40 interruptions/discontinuations) that were followed for at least 11 months after interrupting or discontinuing TKI treatment, 7 were still off treatment at the end of the study. Of these 7, all 4 with an MR4.5 or deeper response at the time of discontinuation maintained this response, 2 with MR4 at the time of discontinuation had an MMR, and 1 with MMR at the time of discontinuation had CCyR at the last follow-up. Treatment Interruptions/Discontinuations Due to Side Effects In total, 67% (46/69) of interruptions/discontinuations were due to TKI side effects or intolerance (online suppl. Table 2 ). These occurred mostly while the patients were taking imatinib (20/46; 43%) or dasatinib (17/46; 37%) ( Table 5 ). Among patients reinitiating treatment after interrupting/discontinuing due to side effects, more reinitiations with TKI switching occurred for dasatinib (8/17; 47%) than for imatinib (5/20; 25%). Treatment interruptions/discontinuations due to side effects seemed to occur later in patients on imatinib (median 268 weeks) than in those on dasatinib (51 weeks), but then lasted longer (165 vs. 84 days). Very early treatment interruptions/ discontinuations (after a median of 9 and 4 weeks, respectively) due to side effects were observed for nilotinib and ponatinib.
Treatment Interruptions/Discontinuations Due to Pregnancy or the Wish to Conceive
In total, 6 patients interrupted/discontinued treatment due to their wish to conceive, 3 men and 3 women (Table 6 ). All were younger than 40 years, in the CP of CML. Three had a low Sokal risk score and 1 an intermediate Sokal risk score; no data was available for the remaining 2. All patients interrupting/discontinuing treatment to conceive had at least MMR at the time of interruption/discontinuation: 4/6 with an MMR, 1 with an MR4, and 1 with an MR4.5 or deeper. At the time of treatment interruption/discontinuation, 4/6 patients were using imatinib. Only 2 subsequently reinitiated treatment, both due to a loss of response. One had a complete relapse (no CHR) and the other had CHR before reinitiation. Both reinitiated treatment with the TKI used before interruption (i.e., 1 with imatinib and 1 with nilotinib). The median duration of interruption/discontinuation of TKI treatment among these patients was 253 days. All patients wishing to conceive interrupted/discontinued the treatment for ≥5 months.
Treatment ReInitiations
Treatment was reinitiated after 62% (43/69) of interruptions/discontinuations, 20 of which were reinitiated with a different TKI from the one used before interruption/discontinuation (Table 7) . Most reinitiations (34/43; 79%) occurred following a treatment interruption/discontinuation due to side effects or intolerance. Of the patients on imatinib before the interruption who reinitiated treatment, 18% (6/34) switched to a different TKI. Patients previously on nilotinib, dasatinib, and ponatinib reinitiated with a different TKI in 42% (5/12), 40% (8/20) , and 33% (1/3) of cases, respectively. Among patients who reinitiated treatment with a different TKI, most interruptions/discontinuations were due to side effects or intolerance to the previous TKI.
None of the patients who interrupted TKI treatment for a TFR attempt had their treatment reinitiated (0/6). Of the 6 who interrupted the treatment due to the wish to conceive, 33% (2/6) had treatment reinitiated. One of 2 patients who had interrupted TKI treatment by spontaneous request had treatment reinitiated. Of the patients that had interrupted TKI treatment due to side effects or intolerance, 74% (34/46) had treatment reinitiated.
The reasons for treatment reinitiation were either loss of response in 47% (20/43) of the cases, the resolution of side effects in 37% (16/43), and another reason in 16% (7/43).
Of the 40 interruptions/discontinuations that were followed up for at least 11 months, 33 treatment reinitiations were reported until study end. These included 4 patients with an MR4.5 or deeper at the time of discontinuation who reinitiated treatment due to a resolution of side effects but maintained their response.
Patients who reinitiated treatment had higher BCR-ABL1 expression at the time of reinitiation than at the time of treatment interruption/discontinuation (not shown).
Discussion
This is the first study to assess interruptions/discontinuations of TKI treatment in Belgian CML patients in a real-life setting. All 60 patients with TKI interruptions/ discontinuations were in the CP of CML, mainly with a low or intermediate Sokal risk score. Out of a total of 69 TKI interruptions/discontinuations recorded, more than three-quarters occurred while on first-or second-line treatment, and nearly half while on imatinib. These findings are consistent with the fact that imatinib is a well- established treatment option in the front-line CML setting in Belgium. Although TKI treatment is currently viewed as a lifelong treatment, discontinuing or interrupting it is considered in certain cases, e.g., when side effects impact severely on the quality of life, or the case of a pregnancy or the wish to conceive. Health care costs can also be a limiting factor. So far, cessation of treatment is not yet daily clinical practice for physicians. Current recommendations state that following TKI treatment stop, the MR should be monitored once per month during the first 6-12 months, although only 4 analyses per year are reimbursed by the Belgian health authorities [5, 24] . An MMR is considered optimal for survival, but to achieve a successful discontinuation of treatment, a sustained DMR is required [25] . In our survey, the MR at the time of treatment discontinuation/interruption was MMR or deeper in three-quarters of the cases. These MRs at the time of treatment discontinuation/interruption were achieved after a median of 85, 27, and 63 weeks, respectively, in patients with MMR, MR4, and MR4.5.
The main reason for TKI treatment interruption/discontinuation identified in our study was the presence of side effects or intolerance; however, treatment was later reinitiated in three-quarters of these cases, and with a different TKI in 39%. Most interruptions/discontinuations due to side effects or intolerance occurred in patients on imatinib (43%) and dasatinib (37%). This reflects current practice because most patients were being treated with imatinib or dasatinib at the time of the study. Less than one-tenth of the interruptions/discontinuations occurred due to a TFR attempt; none of these patients reinitiated treatment for the duration of our study.
The median duration of TKI treatment interruption/ discontinuation depended on the response at the time of interruption/discontinuation, with the low responders (CHR and CCyR) having a shorter interruption/discontinuation and a quicker monitoring of the response after treatment interruption/discontinuation than participants with at least MMR. The TKI treatment interruption/discontinuation was longer for patients with at least MMR, diagnosed for a longer time, and treated for > 1 year with a first-or second-line TKI. The longest interruptions/discontinuations were recorded for patients on imatinib, which is also in line with the fact that imatinib was the most widely used TKI at the time of this study.
Following almost two-thirds of TKI interruptions/discontinuations, treatment was reinitiated. As expected, if treatment was interrupted/discontinued due to side effects or intolerance, it was then reinitiated (in almost No I/Ds were recorded for bosutinib or other TKIs. I/D, interruption/discontinuation; n, number of treatment I/Ds (overall) or reinitiations (restarted treatment). a n = 69; b n = 43; c n = 20. three-quarters of cases). Three-quarters of these reinitiations occurred with a different TKI. Most low responders and patients with an MMR reinitiated treatment. The treatment reinitiation rate was higher in patients with a shorter interval between CML diagnosis and TKI treatment interruption/discontinuation and a shorter duration of TKI treatment. This is consistent with the current knowledge of successful TFR. At treatment reinitiation, no CHR was reported in 19% of the cases; a CHR or CCyR was reported in about half of the cases.
The main reason for TKI treatment reinitiation was the loss of response after treatment interruption/discontinuation or the resolution of side effects. The first was more frequent in patients with MMR or a better response at the time of the interruption/discontinuation, while the latter occurred more frequently in patients with a low response. Of note, no CML patients developed acceleratedphase CML or a blast crisis; all remained in CP-CML.
As expected, follow-up of MR after interruption/discontinuation was fast (an overall median time of 51 days). However, this is slightly longer than the 1-month interval currently recommended in Belgian guidelines in cases of TFR attempts and can probably be partly attributed to the lack of reimbursement.
Both male and female participants interrupted/discontinued treatment in an attempt to conceive. Although the impact of TKI treatment on fertility or pregnancy outcome is not fully elucidated, there is no formal contraindication for procreation while on imatinib and dasatinib in male patients [29, 30] . However, female patients should discontinue TKI treatment during conception and pregnancy, and all pregnancies should be planned to achieve at least an MMR before interruption/discontinuation. In our study, all patients wishing to conceive had an MMR or better response, and only one-third reinitiated treatment during the time the survey was conducted, due to a loss of response. Currently, Belgian experts recommend a treatment interruption/discontinuation of ≥3 months to attempt procreation [27] ; in our study, the median length of interruption/ discontinuation was 253 days (approx. 8.3 months).
Even though TKI therapies in CML are considered a life-long treatment, this study has shown that in a real-life setting, interruption or discontinuation occurs quite frequently in the CML population and for a variety of reasons.
The proportion of patients who interrupted treatment to attempt a long-term TFR was very small in this study (9% of all cases). This is in line with the fact that national guidelines as well as the most recent ELN guidelines of 2013, applicable at the time of TKI interruption of the patients in this study, suggest continuing TKI therapy indefinitely and that discontinuation is appropriate only in a controlled clinical trial [5] .
A few patients interrupted TKI treatment due to the wish to conceive (9% of all cases). Indeed, conception and pregnancy are contraindicated during TKI treatment [5] . Belgian national guidelines also state that female patients who wish to conceive are advised to discontinue any TKI during conception and pregnancy [27] .
The presence of side effects or intolerance was the most frequently reported reason to interrupt or discontinue TKI treatment in our study (67% of all cases). The management of side effects is increasingly important as therapy is potentially for life and multiple TKIs are available [2] . Belgian national guidelines recommend discontinuing TKI therapy in cases of severe hepatic toxicity, severe skin rash, pancreatitis, and pulmonary hypertension [27] . In addition, it is known that low-grade chronic toxicities that substantially impact a patient's quality of life (and for other reasons) can lead to non-adherence which is commonly reported in CML. The 2013 ELN recommendations state that a reduction or interruption of treatment must only be done if optimal management of the AE cannot be accomplished in other ways, and frequent monitoring is needed to detect resolution of the AE as early as possible [23] .
Eight patients with a follow-up of at least 11 months had MR4.5 or deeper at discontinuation; 4 of them restarted treatment due to a resolution of side effects while maintaining their response and 4 remained with MR4.5 and did not restart TKI treatment at the end of the study.
This retrospective study had several limitations. First, to set a threshold for significant treatment interruptions/ discontinuations in terms of duration, patients needed to have a TKI interruption/discontinuation of at least 4 continuous weeks to be included in the study. As such, we were not able to collect any real-life data on shorter TKI interruptions/discontinuations, which are also frequently observed in CML and contribute to non-adherence. We also did not make a distinction between therapy interruptions that were recommended and those not recommended by the treating physician. The study was retrospective, with a limited follow-up time (i.e., the interval between the TKI interruption and data collection). This meant that some variables were not captured for patients who were still off therapy at time of data collection. The kinetics of the response after the TKI interruption in the function of time were also not captured. No information was collected about the TKI dose being taken by patients at DOI: 10.1159/000499329 the time of therapy interruption. This Belgian study included only 60 patients and provided descriptive data only and should be interpreted as such. Nonetheless, it study contains interesting real-life practice data complementing that collected in clinical trials of CML.
In conclusion, the main reasons for TKI interruption/ discontinuation in this retrospective study were side effects of or intolerance to the TKI, with TFR attempts representing only a small percentage. Irrespective of the reason for TKI interruption, almost half of the patients reinitiated treatment due to a loss of response. The results of this study underline the need of an individual approach for the optimal management of CML patients.
